We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

DxGen Corp.

DxGenco is Point-Of-Care (POC) IVD company focused on developing multi-markers for people with diabetes and tuberculo... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

DxGen and Precision Diabetes Partner to Launch New Diabetes POC Testing Analyzer in US

By LabMedica International staff writers
Posted on 24 Aug 2022
Print article
Image: EpithodAutoDx is a fully-automatic POC analyzer that measures a comprehensive profile of diabetes tests (Photo courtesy of DxGen Corp.)
Image: EpithodAutoDx is a fully-automatic POC analyzer that measures a comprehensive profile of diabetes tests (Photo courtesy of DxGen Corp.)

The diabetes point-of-care (POC) testing market continues to expand rapidly as the diabetic epidemic continues unabated. The global POC A1c testing market alone is estimated to be worth USD 500 million and is expected to grow to USD 680 million by 2023. Now, a strategic partnership to launch a fully-automatic POC analyzer in the US will provide a suite of diabetes tests in physician offices, smaller laboratories, outpatient clinics, and hospitals across the country, allowing clinicians to provide “real-time,” actionable test results to patients, rather than waiting for several days for standard laboratory test results.

DxGen Corp. (Seoul, Korea) and Precision Diabetes, Inc. (Raleigh, NC, USA) have entered in an exclusive agreement in the U.S. to launch Epithod AutoDx, a fully-automatic point-of-care (POC) analyzer that measures a comprehensive profile of diabetes tests. The initial test menu will begin with hemoglobin A1c, C-reactive protein, and urinary albumin, with additional diabetes tests to be added in the near future.

EpithodAutoDx is a small analyzer with a very user-friendly design and easy operation, making it uniquely suitable for point-of-care settings such as physician offices, smaller laboratories, outpatient clinics, and hospitals. By providing a suite of diabetes tests in these settings, clinicians will be able to provide “real-time,” actionable test results to patients, rather than waiting for several days for standard laboratory test results. TheEpithod AutoDx is well positioned to become a dominant player in the rapidly expanding diabetes POC testing market as the diabetes test menu continues to expand.

“By integrating Epithod AutoDx into our diabetes product portfolio, we are demonstrating our commitment to providing healthcare professionals access to important clinical diagnostics focused on early detection, prevention, and management of diabetes, prediabetes, and associated complications in point-of-care settings,” said Eric Button, Founder and CEO of Precision Diabetes, Inc.“As we continue to build the diabetes test menu, we believe we will have the most user-friendly and comprehensive POC diabetes test solution in the marketplace.”

“The COVID-19 pandemic has accelerated on-site testing worldwide, and Epithod AutoDx can measure multiple diabetes tests on one point-of-care analyzer, providing rapid results that enable clinicians to make faster clinical decisions,” said Jinwoo Lee of DxGen. “The strategic partnership in the United States between the two companies creates a powerful combination to help people with prediabetes and diabetes.”

Related links:

DxGen Corp
Precision Diabetes


Gold Supplier
SARS-CoV-2 IgG ELISA Test
SARS-CoV-2 IgG ELISA Kit
New
β-hCG Test
RAMP TOTAL β-hCG Test
New
Silver Supplier
SARS-CoV-2, Influenza A/B Test
REALQUALITY ABFlu-Cov-2
New
Cytomegalovirus ELISA Test
Captia Cytomegalovirus (CMV) IgM EIA

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: Mindray ToRCH reagents deliver excellent seroconversion sensitivity (Photo courtesy of Mindray)

Mindray Launches High-Sensitivity and High-Specificity ToRCH Panel

Mindray (Shenzhen, China) has launched the ToRCH Panel that provides high-quality assays to meet different clinical needs. Thanks to the improved raw materials, processes, formulas, reaction models, and... Read more

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.